The study was done to assess the feasibility and acceptability of a second-trimester medical abortion regimen using mifepristone and sublingual misoprostol with no maximum number of misoprostol doses in Uzbekistan and Ukraine.
This study enrolled 306 women with pregnancies of 13–22 weeks in Uzbekistan and Ukraine. The study staff interviewed women. The questions that were asked were mainly about the intensity of pain, side effects, and satisfaction with the procedure. The primary outcome was the rate of complete uterine evacuation without surgical intervention or oxytocin at 15 hours after the first dose of misoprostol.
Most women found pain and side effects to be acceptable or very acceptable. They reported high satisfaction with the procedure.
The study concluded through its findings that the medical abortion in pregnancies of 13–22 weeks with 200 mg mifepristone followed 24–48 hours later by 400 μg sublingual misoprostol administered every 3 hours until complete expulsion is effective, safe, and acceptable to women. Women can be given the option to take mifepristone at home and return to the hospital.